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1. INTRODUCTION {#dom12797-sec-0005}
===============

Physical activity is one of the three cornerstone recommendations (along with diet and medication) in the treatment of type 2 diabetes.[1](#dom12797-bib-0001){ref-type="ref"}, [2](#dom12797-bib-0002){ref-type="ref"}, [3](#dom12797-bib-0003){ref-type="ref"}, [4](#dom12797-bib-0004){ref-type="ref"}, [5](#dom12797-bib-0005){ref-type="ref"} Exercise training improves aerobic capacity and muscular strength and is often associated with fat loss and increased muscle mass. Furthermore, exercise training has a beneficial effect on insulin‐mediated glucose uptake and is associated with increased glucose transporter 4 (GLUT4) expression and improved insulin signalling in skeletal muscle.[6](#dom12797-bib-0006){ref-type="ref"}, [7](#dom12797-bib-0007){ref-type="ref"} Despite several studies reporting significant reductions in glycated haemoglobin (HbA1c) of 0.4% to 0.6% after increasing the level of physical activity, it is often not sufficient to normalize glycaemic control in patients with type 2 diabetes.[2](#dom12797-bib-0002){ref-type="ref"}, [8](#dom12797-bib-0008){ref-type="ref"}, [9](#dom12797-bib-0009){ref-type="ref"} Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone secreted from enteroendocrine L cells located in the distal jejunum and ileum in response to meal ingestion. GLP‐1 is known mainly for its glucose‐lowering and satiety‐promoting effects.[10](#dom12797-bib-0010){ref-type="ref"} Since 2006, GLP‐1 receptor agonists (GLP‐1RAs) have been used for the treatment of patients with type 2 diabetes.[11](#dom12797-bib-0011){ref-type="ref"} Liraglutide is a once‐daily administered GLP‐1RA with beneficial effects on HbA1c levels, body weight and body composition in obese dysregulated patients with type 2 diabetes.[11](#dom12797-bib-0011){ref-type="ref"} Nevertheless, a substantial proportion of GLP‐1RA‐treated patients do not reach glycaemic targets.

Exercise and GLP‐1RAs have each been used for the treatment of patients with type 2 diabetes for several years; however, the combination of the two has, to our knowledge, never been evaluated in prospective trials before. We hypothesized that exercise training combined with GLP‐1RA treatment would result in clinically relevant improvements in HbA1c and a range of other health‐related variables, in obese, sedentary and dysregulated patients with established type 2 diabetes.

2. METHODS {#dom12797-sec-0006}
==========

2.1. Study design and endpoints {#dom12797-sec-0007}
-------------------------------

The study was a 16‐week, randomized, double‐blind, placebo‐controlled study conducted at the Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark. The study was conducted in accordance with the international Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. The study was designed and conducted by the authors, and the authors vouch for the data and analyses, as well as the fidelity of this report to the study protocol. The study was an investigator‐initiated study, sponsored by Novo Nordisk, but Novo Nordisk had no role in the study design, data analysis or reporting of results. The primary endpoint was change in HbA1c (from baseline until end of study (16 weeks)). Secondary outcomes included changes in body weight, body composition, maximum oxygen uptake (VO~2max~), fasting plasma glucose (FPG), serum insulin, serum C‐peptide, plasma glucagon, plasma concentrations of incretin hormones, liver enzymes, lipids, blood pressure, heart rate and quality of life (QoL). Further secondary outcomes, insulin resistance and β‐cell function, were evaluated by homeostatic model assessment (HOMA‐IR and HOMA‐β, respectively).

Patients were recruited from the Diabetes Outpatient Clinic at Gentofte Hospital, Denmark, and through advertisement. Oral and written informed consent were obtained before inclusion. Inclusion criteria were: age \>18 years; type 2 diabetes treated with diet and/or metformin; HbA1c between 7% and 11% (53‐97 mmol/mol), body mass index (BMI) \> 25 kg/m^2^; and sedentary lifestyle (self‐reported physical activity \<150 min/wk). Exclusion criteria were clinically relevant cardiovascular disease, impaired liver function, anaemia and/or impaired renal function. Eligible patients were randomly assigned to either exercise training plus liraglutide (exercise plus liraglutide) or to exercise training plus placebo (exercise plus placebo) for 16 weeks (Figure [1](#dom12797-fig-0001){ref-type="fig"}). An employee otherwise not involved in the study carried out the randomization at a 1:1 ratio from a prespecified randomization list. The exercise training consisted of three 60‐minute supervised training sessions per week (in groups). Twice per week the patients participated in spinning sessions (Indoor Body Bike Supreme; Pedan, Køge, Denmark) with an average intensity of 65% to 85% of maximum heart rate (monitored by RS300X; Polar, Kempele, Finland). The programme for spinning sessions was modelled on traditional spinning programs with music and focusing on cardio‐training with incorporated high‐intensity intervals of 30‐second sprints (4‐10 repetitions) followed by 1 minute of active recovery. The third session consisted of 8 different resistance exercises (squat, lunges, biceps, triceps, whole‐body \[modulated Olympic lift\], bench press, shrugs and plank), and 3 sets of 12 repetitions with 30‐second to 45‐second rests between each set in order to recruit the major muscle groups. Resistance exercise training was performed with barbells (Reebok, Canton, Massachusetts) with individually adjustable weight loads. Exercise training compliance was defined as no less than 85% participation. All exercise sessions were conducted under the supervision of trained exercise physiologists (P.M. and S.N.). The patients were repeatedly instructed not to change their diet or physical activity during the study period except for the study intervention. A questionnaire describing the frequency and composition of the daily food intake before, midway and at the end of the study was used. The study drugs used were the GLP‐1 analogue, liraglutide (Victoza), and placebo, which were supplied by Novo Nordisk in blinded pens for subcutaneous (s.c.) injections. After baseline evaluation, the patients received once‐daily s.c. injections of 0.1 mL of study medication (0.6 mg liraglutide or placebo) in the evening for 1 week, 0.2 mL (1.2 mg liraglutide or placebo) the following week and thereafter 0.3 mL (1.8 mg liraglutide or placebo) for the remaining study period. Patients were examined in the fasting state at baseline and at the end of the study with blood samples, blood pressure, resting heart rate, dual‐energy X‐ray absorptiometry scan and physical fitness test. End of study examinations were performed after the last liraglutide or placebo dose was given, the evening before and 42 to 75 hours after the last bout of exercise.

![Consort flow diagram showing patient numbers at each stage of the study.](DOM-19-172-g002){#dom12797-fig-0001}

2.2. Experimental procedures {#dom12797-sec-0008}
----------------------------

A dual‐energy X‐ray absorptiometry scan (DPX--IQ Lunar, General Electric Lunar Corporation, Madison, Wisconsin) was performed to assess body composition. Fat distribution was evaluated as the relative proportion of fat tissue in the android (abdominal) and the gynoid (hip and thigh) regions. The physical fitness level of the patients (VO~2max~) was estimated from a two‐step sub‐maximum bicycle test at baseline and at the end of the intervention. Each patient worked at two different workloads on a stationary bicycle ergometer (Monark ergomedic 839 E, Monark, Vansbro, Sweden). The workload was increased until a heart rate of 110 to 120 beats/min was achieved. At steady‐state heart rate, oxygen uptake was measured (MasterScreen CPX system; Intramedic, Gentofte, Denmark). The workload was then increased to achieve a heart rate of 140 to 160 beats/min and oxygen uptake at steady state was measured again. The duration of the test was 10 to 12 minutes. VO~2max~ was estimated from the measurements of VO~2~ during the two‐point step test and an estimation of maximum heart rate.[12](#dom12797-bib-0012){ref-type="ref"} Resting heart rate and blood pressure were measured on the left arm after the patients had rested for 10 minutes. A health‐related questionnaire, the Short‐Form‐36 Health Survey, was used to evaluate changes in QoL.[13](#dom12797-bib-0013){ref-type="ref"}

2.3. Analytical assessment {#dom12797-sec-0009}
--------------------------

A colorimetric assay was used to measure HbA1c (Vitros 5.1 FS; Ortho‐Clinical Diagnostics, Linden, New Jersey). Concentrations of glucose were measured by the glucose oxidase method, using a glucose analyser (Yellow Springs Instrument model 2300 STAT plus analyser; YSI Inc., Yellow Springs, Ohio). Insulin and C‐peptide concentrations were measured using a two‐sided electrochemiluminescence immunoassay (Siemens Healthcare, Ballerup, Denmark).[14](#dom12797-bib-0014){ref-type="ref"}, [15](#dom12797-bib-0015){ref-type="ref"} Concentrations of total GLP‐1, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon were measured by radioimmunoassays, as previously described.[16](#dom12797-bib-0016){ref-type="ref"}, [17](#dom12797-bib-0017){ref-type="ref"} Assessment of triglycerides and lipids was measured using reflectance spectrophotometry (Vitros 5.1, Johnson & Johnson, Ortho‐Clinical Diagnostics, New Brunswick, New Jersey).

2.4. Calculations and statistical methods {#dom12797-sec-0010}
-----------------------------------------

Steady‐state insulin resistance (HOMA‐IR) and β‐cell function (HOMA‐β) were estimated using the HOMA2 calculator.[18](#dom12797-bib-0018){ref-type="ref"} The statistical analyses were performed using STATA 12.1 (STATA Corp, LP, College Station, Texas). Data are reported as mean ± standard deviation; in case of non‐normal distribution, data were log‐transformed and back‐transformed. Estimates are reported as geometric means with 95% confidence interval (CI). Differences between mean values in the two groups were analysed using Student\'s *t*‐test. Analyses of between‐group differences were performed by analysis of covariance (ANCOVA) with the end‐of‐study value as the dependent variable and the baseline value as the independent variable. *P* values of \<.05 were considered to indicate statistical significance. The statistical analyses were performed by P.M. and M.T.J.

2.5. Study registration {#dom12797-sec-0011}
-----------------------

The study was approved by the Danish Medicines Agency (EudraCT number: 2011‐002739‐24) and the Scientific‐Ethical Committee of the Capital Region of Denmark (registration number: H‐4‐2011‐073), notified to the Danish Data Protection Agency (reference number 2007‐58‐0015) and registered at [ClinicalTrials.gov](http://www.ClinicalTrials.gov) (ID: NCTO1455441). The study conformed to the latest revision of the Declaration of Helsinki. The study was monitored by the Good Clinical Practice unit of University of Copenhagen and was conducted in compliance with the protocol and national guidelines including Clinical Trials Directive 2001/20/EC.

3. RESULTS {#dom12797-sec-0012}
==========

From December 2011 to March 2013, a total of 34 patients were enrolled in the study, of whom 33 completed the full study. One patient was excluded because of lack of exercise compliance. Patient characteristics were similar in the two groups (Table [1](#dom12797-tbl-0001){ref-type="table-wrap"}). Medical treatment was similar in the groups and remained unchanged during the study. Besides metformin, patients received no medication known to interfere with glucose metabolism.

###### 

Baseline characteristics of the patients

                                   **Exercise plus liraglutide**   **Exercise plus placebo**   ***P***
  -------------------------------- ------------------------------- --------------------------- ---------
  Age, years                       56.5 ± 9                        55.6 ± 12                   .79
  Sex: female, n (%)               4 (24)                          6 (38)                      .38
  Duration of diabetes, years      6.0 ± 5.2                       3.7 ± 3.3                   .20
  Diet/metformin, n                0/17                            3/13                        
  Daily dose metformin, mg         1374 ± 607                      1628 ± 936                  
  FPG, mM                          9.9 ± 2.7                       10.2 ± 3.1                  .91
  HbA1c, %                         8.2 ± 1.4                       8.0 ± 1.2                   .58
  HbA1c, mmol/mol                  66.0 ± 16.0                     64.0 ± 13.0                 
  Body weight, kg                  101.0 ± 14.5                    96.8 ± 17.4                 .45
  BMI, kg/m^2^                     32.5 ± 3.7                      32.4 ± 5.2                  .95
  VO~2max~ estimated, L O~2~/min   2.9 ± 0.9                       2.5 ± 0.7                   .11

Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; VO ~2max~, maximum oxygen uptake.

Data are presented as mean ± standard deviation.

3.1. Glycated haemoglobin {#dom12797-sec-0013}
-------------------------

Patients receiving exercise plus liraglutide experienced pronounced reductions in HbA1c, whereas no significant change was observed in the exercise plus placebo group (Table [2](#dom12797-tbl-0002){ref-type="table-wrap"}, Figure [2](#dom12797-fig-0002){ref-type="fig"}A). In the exercise plus liraglutide group, 77% of patients obtained an HbA1c \<7% (53 mmol/mol) and 53% normalized their HbA1c concentration (\<6.0% \[42 mmol/mol\]). In the exercise plus placebo group, the corresponding values were 25% and 6%, respectively (Figure [2](#dom12797-fig-0002){ref-type="fig"}F).

###### 

Changes between baseline and end of study

                                                        **Exercise plus liraglutide**   **Exercise plus liraglutide**                              **Difference**   **Exercise plus placebo**   **Exercise plus placebo**                                 **Difference**   ***P* value between groups**
  ----------------------------------------------------- ------------------------------- ---------------------------------------------------------- ---------------- --------------------------- --------------------------------------------------------- ---------------- ------------------------------
  **Glucose**                                                                                                                                                                                                                                                              
  HbA1c, %                                              8.2 ± 1.4                       6.2 ± 0.7[\*\*\*](#dom12797-note-0007c){ref-type="fn"}     −2.0 ± 1.2       8.0 ± 1.2                   7.7 ± 1.5                                                 −0.3 ± 0.9       \<.001
  HbA1c, mmol/mol                                       66.0 ± 16.0                     44.0 ± 8.0[\*\*\*](#dom12797-note-0007c){ref-type="fn"}    −22.0 ± 14.0     64.0 ± 13.0                 61.0 ± 17.0                                               −3.0 ± 10.0      .001
  FPG, mM                                               10.4 ± 3.4                      7.0 ± 1.6[\*\*\*](#dom12797-note-0007c){ref-type="fn"}     −3.4 ± 2.3       10.0 ± 3.1                  9.8 ± 3.7                                                 −0.3 ± 2.6       .010
  **Incretin hormones and glucagon (fasting levels)**                                                                                                                                                                                                                      
  Glucagon, pM                                          9.6 ± 2.9                       9.4 ± 3.2                                                  −0.3 ± 3.2       9.4 ± 3.7                   8.2 ± 2.1                                                 −1.2 ± 3.2       .23
  GLP‐1, pM                                             18.7 ± 3.9                      19.3 ± 5.6                                                 +0.6 ± 6.3       20.1 ± 8.2                  18.1 ± 5.7                                                −2.0 ± 5.4       .30
  GIP, pM                                               13.9 ± 4.0                      16.3 ± 5.2                                                 +2.4 ± 7.1       13.1 ± 4.0                  17.0 ± 8.5                                                +4.0 ± 9.3       .82
  **Body composition**                                                                                                                                                                                                                                                     
  Body weight, kg                                       101.0 ± 14.5                    97.6 ± 14.9[\*\*\*](#dom12797-note-0007c){ref-type="fn"}   −3.4 ± 2.9       96.8 ± 17.4                 95.2 ± 17.7                                               −1.6 ± 3.2       .10
  Body mass index, kg/m^2^                              32.5 ± 3.7                      31.3 ± 3.4[\*\*\*](#dom12797-note-0007c){ref-type="fn"}    −1.1 ± 1.1       32.4 ± 5.2                  31.8 ± 5.1[\*](#dom12797-note-0007a){ref-type="fn"}       −0.5 ± 1.0       .11
  Fat percent, %                                        34.3 ± 6.3                      31.8 ± 6.8[\*\*\*](#dom12797-note-0007c){ref-type="fn"}    −2.5 ± 1.4       37.0 ± 6.5                  34.8 ± 7.0[\*\*\*](#dom12797-note-0007c){ref-type="fn"}   −2.2 ± 1.9       .77
  Gynoid fat, %                                         34.4 ± 9.1                      32.5 ± 9.6[\*\*\*](#dom12797-note-0007c){ref-type="fn"}    −2.0 ± 1.6       38.8 ± 9.2                  36.3 ± 8.6[\*\*\*](#dom12797-note-0007c){ref-type="fn"}   −2.4 ± 1.9       .53
  Android fat, %                                        44.6 ± 4.5                      41.4 ± 5.2[\*\*\*](#dom12797-note-0007c){ref-type="fn"}    −3.2 ± 2.3       45.9 ± 6.5                  42.8 ± 7.8[\*\*\*](#dom12797-note-0007c){ref-type="fn"}   −3.1 ± 3.0       .97
  Lean body mass, kg                                    63.3 ± 12.2                     63.4 ± 12.8                                                0.1 ± 2.2        58.0 ± 12                   58.7 ± 12.1                                               0.7 ± 1.5        .42
  **Blood pressure and heart rate**                                                                                                                                                                                                                                        
  SBP, mm Hg                                            136.2 ± 8.9                     130.8 ± 8.8[\*\*](#dom12797-note-0007b){ref-type="fn"}     −5.4 ± 7.4       136.4 ± 11.0                135.8 ± 11.6                                              −0.6 ± 11.1      .11
  DBP, mm Hg                                            82.1 ± 7.0                      81.5 ± 7.2                                                 −0.5 ± 4.5       84.1 ± 7.0                  81.8 ± 8.0                                                −2.3 ± 5.5       .41
  Resting heart rate ‐ bpm                              69.9 ± 8.9                      71.3 ± 9.4                                                 +1.4 ± 7.6       70.1 ± 11.1                 68.1 ± 12.7                                               −2.0 ± 7.7       0.22
  VO~2max~, L/O~2~/min                                  2.9 ± 0.9                       3.4 ± 1.1[\*\*\*](#dom12797-note-0007c){ref-type="fn"}     +0.5 ± 0.5       2.5 ± 0.7                   2.9 ± 0.8[\*\*](#dom12797-note-0007b){ref-type="fn"}      +0.4 ± 0.4       .92
  **Lipid profile**                                                                                                                                                                                                                                                        
  Total cholesterol, mM                                 4.7 ± 1.1                       4.4 ± 1.3                                                  −0.3 ± 0.8       4.2 ± 0.9                   4.3 ± 0.9                                                 +0.1 ± 0.9       .44
  HDL cholesterol, mM                                   1.2 ± 0.4                       1.2 ± 0.3                                                  −0.02 ± 0.2      1.2 ± 0.3                   1.3 ± 0.4                                                 +0.1 ± 0.2       .50
  LDL cholesterol, mM                                   2.6 ± 1.0                       2.4 ± 1.2                                                  −0.2 ± 0.8       2.2 ± 0.9                   2.3 ± 0.8                                                 +0.1 ± 0.8       .35
  VLDL cholesterol, mM                                  0.8 ± 0.5                       0.7 ± 0.4                                                  −0.1 ± 0.4       0.7 ± 0.3                   0.7 ± 0.3                                                 −0.07 ± 0.2      .65

Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose; GIP, glucose‐dependent insulinotropic polypeptide; GLP‐1, glucagon‐like peptide‐1; SBP, systolic blood pressure; VO ~2max~, maximum oxygen uptake.

Data are mean ± standard deviation

P \< .05,

P \< .01 and

P \< .001 compared with baseline value within the group.

![Glycated haemoglobin **(** HbA1c), fasting plasma glucose (FPG), body composition and maximum oxygen uptake (VO~2max~). A, HbA1c in exercise plus liraglutide (green at baseline and green pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). B, FPG in exercise plus liraglutide (green at baseline and green pattern), exercise plus placebo (blue at baseline and blue pattern at end of study). C, Differences in body weight in exercise plus liraglutide (green blue at baseline and green pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). D, Differences in fat mass in exercise plus liraglutide (green at baseline and blue pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). E, Estimated VO~2max~ in exercise plus liraglutide (green at baseline and green pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). F, Proportions of patients archiving HbA1c targets after the intervention. Exercise plus liraglutide (green) exercise plus placebo (blue). Data are mean ± standard error of the mean. Significant differences (P \< .05) between the groups are indicated by asterisks (\*) and significant differences (P \< .05) within the groups are indicated by hatch signs (^\#^).](DOM-19-172-g001){#dom12797-fig-0002}

3.2. Body weight and body composition {#dom12797-sec-0014}
-------------------------------------

The mean (range) body weight was reduced by 3.4 (−8.5 kg to +2.3) kg in patients treated with exercise plus liraglutide, whereas it remained unchanged with exercise alone (−1.6 \[−9.3 to +2.8\] kg; Figure [2](#dom12797-fig-0002){ref-type="fig"}C). A significant reduction in body fat (%) was observed in both groups (Table [2](#dom12797-tbl-0002){ref-type="table-wrap"}, Figure [2](#dom12797-fig-0002){ref-type="fig"}D). Furthermore, gynoid and android fat (%) decreased significantly in both groups, with no difference between the groups. Lean body mass was unchanged from baseline in both groups (Table [2](#dom12797-tbl-0002){ref-type="table-wrap"}). Data from the simple questionnaire inquiring about the frequency and composition of the daily food intake before, midway and at the end of the study showed little or no change in food intake between the groups over 16 weeks.

3.3. Exercise compliance and physical fitness {#dom12797-sec-0015}
---------------------------------------------

Overall exercise compliance was 89% ± 4%, equal to \~2 hours and 41 min/wk during the 16‐week intervention period. During spinning sessions, the mean intensity was 77% ± 2% of estimated maximum heart rate, with no difference between the groups. VO~2max~ increased significantly, by \~17% in both groups, after 16 weeks (Figure [2](#dom12797-fig-0002){ref-type="fig"}E).

3.4. FPG, insulin, C‐peptide and HOMA‐IR/β {#dom12797-sec-0016}
------------------------------------------

A significant effect on FPG was seen with exercise plus liraglutide, whereas exercise plus placebo had no effect on FPG level (Figure [2](#dom12797-fig-0002){ref-type="fig"}B). No changes were observed in fasting levels of insulin and C‐peptide, respectively, in any of the groups. The estimated HOMA‐IR and estimated steady‐state β‐cell function, HOMA‐β, were both significantly improved with exercise plus liraglutide, whereas no changes were observed with exercise plus placebo (Table [3](#dom12797-tbl-0003){ref-type="table-wrap"}).

###### 

Changes in insulin resistance, β‐cell function and liver enzymes

                                        **Exercise plus liraglutide**   **Exercise plus liraglutide**                                     **Difference**   **Exercise plus placebo**                                      **Exercise plus placebo**   **Difference**   ***P* value between groups**
  ------------------------------------- ------------------------------- ----------------------------------------------------------------- ---------------- -------------------------------------------------------------- --------------------------- ---------------- ------------------------------
  **Insulin, C‐peptide and HOMA2**                                                                                                                                                                                                                                     
  Insulin, pM                           118 (98--141)                   111 (91--135)                                                     −7               102 (71--147)                                                  93 (63--138)                −9               .66
  C‐peptide, pM                         901 (781--1040)                 913 (814--1023)                                                   +12              873 (700--1087)                                                799 (634--1008)             −74              .21
  HOMA2‐IR, insulin                     2.6 (2.2--3.1)                  2.2 (1.8--2.7)[\*\*](#dom12797-note-0010a){ref-type="fn"}         −0.4             2.2 (1.5--3.2)                                                 2.0 (1.4--3.1)              −0.2             .63
  HOMA2‐IR, C‐peptide                   2.6 (2.3--3.0)                  2.2 (2.0--2.5)[\*\*](#dom12797-note-0010a){ref-type="fn"}         −0.4             2.4 (1.9--3.1)                                                 2.4 (1.9--3.1)              +0.02            .023
  HOMA2‐β, insulin                      45.4 (32.7--63.1)               86.5 (70.1--106.7)[\*\*\*](#dom12797-note-0010b){ref-type="fn"}   +41.1            44.6 (30.1--66.3)                                              45.7 (30.3--69.1)           +1.0             \<.0001
  HOMA2‐β, C‐peptide                    45.1 (33.4--60.9)               86.7 (70.7--106.3)[\*\*\*](#dom12797-note-0010b){ref-type="fn"}   +41.6            47.9 (35.5--64.6)                                              51.6 (36.8--72.3)           +3.8             \<.0001
  **Triglycerides and liver enzymes**                                                                                                                                                                                                                                  
  Triglycerides, mM                     1.7 (1.2--2.6)                  1.5 (1.0--2.1)                                                    −0.3             1.6 (1.2--2.3)                                                 1.4 (1.1--1.8)              −0.2             0.95
  ALT, U/L                              47.0 (35.5--62.3)               32.9 (23.2--46.5)[\*\*](#dom12797-note-0010a){ref-type="fn"}      −14.1            38.0 (29.2--49.6)[\*\*](#dom12797-note-0010a){ref-type="fn"}   28.4 (22.7--35.4)           −9.6             0.84
  AST, U/L                              35.7 (28.6--44.5)               33.2 (27.5--40.1)                                                 −2.5             31.2 (25.4--38.4)                                              27.6 (23.7--32.1)           −3.6             0.21

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HOMA, homeostatic model assessment; HOMA‐β, homeostatic model assessment of β‐cell function; HOMA‐IR, homeostatic model assessment of insulin resistance.

Data were log‐transformed due to non‐normal distribution; back‐transformed data are therefore presented as geometric mean (95% CI).

P \< .01 and

P \< .001 compared with baseline value within the group.

3.5. Lipids, liver enzyme, glucagon, GLP‐1 and GIP concentrations {#dom12797-sec-0017}
-----------------------------------------------------------------

Lipids were unchanged after the interventions in both groups (Tables [2](#dom12797-tbl-0002){ref-type="table-wrap"} and [3](#dom12797-tbl-0003){ref-type="table-wrap"}). Alanine transaminase decreased in both groups, whereas aspartate transaminase remained unchanged. No changes in fasting glucagon, GLP‐1 or GIP were observed (Table [3](#dom12797-tbl-0003){ref-type="table-wrap"}).

3.6. Blood pressure and heart rate {#dom12797-sec-0018}
----------------------------------

A significant reduction in systolic blood pressure was found in the exercise plus liraglutide group. No changes were seen in diastolic blood pressure or heart rate (Table [2](#dom12797-tbl-0002){ref-type="table-wrap"}).

3.7. Health‐related QoL {#dom12797-sec-0019}
-----------------------

The health‐related QoL summary score was significantly improved in the general health component and the physical function component in both groups without differences between the groups in any of the components (data not shown).

3.8. Adverse events {#dom12797-sec-0020}
-------------------

Gastrointestinal side effects (mild/moderate and transient nausea, vomiting and diarrhoea) were observed in 24% of the patients in the exercise plus liraglutide group vs 6% in the exercise plus placebo group. No episodes of hypoglycaemia were reported. No serious adverse events (including pancreatitis) were seen in the study.

4. DISCUSSION {#dom12797-sec-0021}
=============

We show, for the first time, that overweight dysregulated and sedentary patients with type 2 diabetes receiving supervised exercise training in combination with the GLP‐1RA liraglutide for 16 weeks achieved: (1) improved glycaemic control; (2) reduction in body weight; and (3) decreased systolic blood pressure compared with patients receiving supervised exercise training combined with placebo. In both groups, improvements in physical fitness, body fat and QoL were observed. Lean body mass was unchanged in both groups, despite weight loss. The overall safety profile of liraglutide was consistent with findings in previous reports.[19](#dom12797-bib-0019){ref-type="ref"}, [20](#dom12797-bib-0020){ref-type="ref"} Interestingly, no changes in resting heart rate were detected in any of the groups, which is in contrast to previous studies with continuously acting GLP‐1RAs, which reported a sustained increase in heart rate of approximately 2 to 4 beats/min.[19](#dom12797-bib-0019){ref-type="ref"}, [20](#dom12797-bib-0020){ref-type="ref"}, [21](#dom12797-bib-0021){ref-type="ref"} Thus, further studies are warranted to elucidate whether exercise training is able to neutralize the well‐known increase in heart rate seen with this class of glucose‐lowering drugs.

An important limitation of the present study is the relatively small sample size of patients, reducing the power to detect subtle changes and increasing the risk of type II statistical errors. Despite this, we were able to demonstrate clinically relevant differences between the two groups. Another limitation of the study is the absence of diet records, which could have shown possible changes in diet after GLP‐1RA treatment. Strengths of the study include the validated methods used; the study was performed as a single‐centre, randomized, double‐blind, placebo‐controlled study, with only few physicians and experienced exercise physiologists involved (all the exercise sessions were performed under the supervision of the same two exercise physiologists). Supervised training was chosen because previous studies have shown improved results with supervision[22](#dom12797-bib-0022){ref-type="ref"} and to support adherence to exercise training and exercise intensity. The period of 16 weeks was selected to allow sufficient time for uptitration of study drug (liraglutide and placebo) so that the maximum recommended dose could be maintained for a full 3‐month period necessary for optimum evaluation of the primary endpoint (HbA1c) and, furthermore to ensure slow adaptation to exercise training to avoid injuries. A GLP‐1RA as a glucose‐lowering drug was selected because of the well‐documented effect on glycaemic control and body weight in type 2 diabetes combined with a low risk of hypoglycaemia.[11](#dom12797-bib-0011){ref-type="ref"} Only a limited number of previous trials with liraglutide have observed reductions in HbA1c up to 1.5% (in the majority of trials reductions ranged from 0.9% to 1.1%).[11](#dom12797-bib-0011){ref-type="ref"} Pratley et al.[23](#dom12797-bib-0023){ref-type="ref"} found HbA1c reduction of 1.5% from baseline HbA1c levels of 8.4% after 26 weeks of treatment. The Liraglutide Effects and Action in Diabetes (LEAD) 4 and 5 studies reported HbA1c decreases of 1.5% and 1.3%, respectively, after 26 weeks of treatment with liraglutide, both in combination with other glucose‐lowering agents (metformin plus rosiglitazone or glimepiride).[24](#dom12797-bib-0024){ref-type="ref"}, [25](#dom12797-bib-0025){ref-type="ref"} Several possible explanations for the near‐normalization of HbA1c after treatment with exercise plus liraglutide in the present study should be considered. At least part of the improved glycaemic control in patients treated with liraglutide relies on the well‐established glucose‐lowering effects of GLP‐1: the glucose‐dependent stimulation of insulin secretion and the inhibition of glucagon secretion[10](#dom12797-bib-0010){ref-type="ref"} and in the brain, respectively.[26](#dom12797-bib-0026){ref-type="ref"} Exercise training is known to increase insulin sensitivity of skeletal muscle in both healthy individuals and in patients with type 2 diabetes[27](#dom12797-bib-0027){ref-type="ref"}, [28](#dom12797-bib-0028){ref-type="ref"} and improves β‐cell function in patients with type 2 diabetes with well‐preserved residual β‐cell function.[10](#dom12797-bib-0010){ref-type="ref"} In individuals with impaired glucose tolerance and in patients with type 2 diabetes, β‐cell function has been shown to be a better predictor of improvement in glycaemic control than insulin sensitivity.[29](#dom12797-bib-0029){ref-type="ref"} Therefore, the beneficial effect of liraglutide on glycaemic control in the present exercise training study seems at least in part to be attributable to the insulinotropic effect of liraglutide, in line with the marked improvement in HOMA‐β (Table [3](#dom12797-tbl-0003){ref-type="table-wrap"}). Nevertheless, the substantial improvement in glycaemic control in the exercise plus liraglutide group, which markedly surpasses what previously has been observed with liraglutide in sedentary patients with type 2 diabetes, is probably attributable to the combination of improved β‐cell function, as well as increased peripheral insulin sensitivity. In the exercise plus placebo group we assume that the lack of improvement in glycaemic control despite an expected increase in muscle insulin sensitivity[27](#dom12797-bib-0027){ref-type="ref"}, [29](#dom12797-bib-0029){ref-type="ref"} may be attributable to inability of the residual β‐cell reserve to benefit from increased insulin sensitivity.

Type 2 diabetes develops as a consequence of insulin resistance and impaired β‐cell function, but it is a very heterogeneous disease with a multifactorial background (eg, genes, lifestyle, obesity, dyslipidaemia and inflammation).[30](#dom12797-bib-0030){ref-type="ref"} This might partially explain why patients with type 2 diabetes, including the patients in the present study, have heterogeneous responses to glucose‐lowering therapies, such as GLP‐1RAs. Exercise benefits most, but not all, individuals[31](#dom12797-bib-0031){ref-type="ref"} and it cannot be ruled out that some of the patients in the present study might have been non‐responders and therefore failed to demonstrate exercise‐induced metabolic improvements. Inflammation in the adipose tissue and dysregulation of adipokines is closely associated with obesity and type 2 diabetes. Also, inflammation has been shown to induce peripheral insulin resistance[32](#dom12797-bib-0032){ref-type="ref"} as well as β‐cell dysfunction.[33](#dom12797-bib-0033){ref-type="ref"}, [34](#dom12797-bib-0034){ref-type="ref"} Several studies have indicated that both GLP‐1 receptor agonists[35](#dom12797-bib-0035){ref-type="ref"} and exercise[36](#dom12797-bib-0036){ref-type="ref"} have anti‐inflammatory effects. The pronounced effect on glycaemic control during the exercise plus liraglutide group, may to some extent, be explained by the well‐known anti‐inflammatory effects of both treatment methods. In larger and longer‐lasting intervention studies, the effects on HbA1c might be less pronounced, as previously found in large‐scale studies; for example, the LEAD 4 and 5 studies.[24](#dom12797-bib-0024){ref-type="ref"}, [25](#dom12797-bib-0025){ref-type="ref"}, [37](#dom12797-bib-0037){ref-type="ref"}

In the present study QoL was not further improved with liraglutide plus exercise despite improved glycaemic control compared with exercise alone. However, QoL was not inferior despite some side effects resulting from liraglutide treatment. These findings could indicate that exercise training is an essential factor for improvements in health‐related QoL. Because adequate lifestyle changes are often difficult to implement and maintain in patients with type 2 diabetes, exercise in combination with liraglutide treatment may be a way to amplify motivation for change when the patients experience noticeable results from the effects of both exercise and liraglutide.

In conclusion, the combination of supervised exercise training and liraglutide induced major improvements in glycaemic control and may be an attractive treatment option for obese, dysregulated patients with type 2 diabetes on diet and/or metformin who are able to perform moderate‐ to high‐intensity exercise training.
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